The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...